Patents Examined by William R. A. Jarvis
  • Patent number: 6734215
    Abstract: Medical conditions are treated by administering a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of its exo-R-mecamylamine, said amount being sufficient to ameliorate the medical condition. The medical conditions include substance addiction (involving nicotine, cocaine, alcohol, amphetamine, opiate, other psychostimulant and a combination thereof), Tourette's Syndrome, and neuropsychiatric disorders (such as bipolar disorder, depression, an anxiety disorder, schizophrenia, a seizure disorder, Parkinson's disease and attention deficit hyperactivity disorder).
    Type: Grant
    Filed: June 15, 2001
    Date of Patent: May 11, 2004
    Assignee: University of South Florida
    Inventors: Douglas Shytle, Paul Sanberg, Mary Newman, Archie A. Silver
  • Patent number: 6730332
    Abstract: The present invention relating to a herbal antiallergic composition which comprises a synergistic mixture of extracts from the fruits of Terminalia chebula, bark of Albizia lebbeck, Terminalia bellerica and Emblica officinalis. The present invention also contains the fruits of Piper longum, Piper nigrum and of rhizomes of Zingiber officinale and thoroughly mixed to get the final composition which has potent antiallergic activity. The invention also relates to a process for the preparation of such composition. The composition is particularly useful for the treatment of allergic conditions.
    Type: Grant
    Filed: December 28, 2001
    Date of Patent: May 4, 2004
    Assignee: Natural Remedies Pvt. Ltd.
    Inventors: Ravindra Kumar Agarwal, Anurag Agarwal
  • Patent number: 6649605
    Abstract: NMDA receptor antagonists, especially mirtazapine, can be used to treat tension-type headaches.
    Type: Grant
    Filed: August 30, 2001
    Date of Patent: November 18, 2003
    Assignee: Head Explorer A/S
    Inventors: Jes Olesen, Lars Bendtsen, Rigmor Jensen, Ulf Madsen
  • Patent number: 6649614
    Abstract: The present invention relates to the treatment of depression and/or anxiety by the administration of a combination of a specific class of NK-1 receptor antagonists and an antidepressant or anti-anxiety agent.
    Type: Grant
    Filed: October 16, 2001
    Date of Patent: November 18, 2003
    Assignee: Merck Sharp & Dohme Ltd.
    Inventors: Emma Joanne Carlson, Nadia Melanie Rupniak
  • Patent number: 6645168
    Abstract: A method and solution for perioperatively inhibiting a variety of pain and inflammation processes at wounds from general surgical procedures including oral/dental procedures. The solution preferably includes multiple pain and inflammation inhibitory at dilute concentration in a physiologic carrier, such as saline or lactated Ringer's solution. The solution is applied by continuous irrigation of a wound during a surgical procedure for preemptive inhibition of pain and while avoiding undesirable side effects associated with oral, intramuscular, subcutaneous or intravenous application of larger doses of the agents.
    Type: Grant
    Filed: July 12, 2002
    Date of Patent: November 11, 2003
    Assignee: Omeros Corporation
    Inventors: Gregory A. Demopulos, Pamela A. Pierce, Jeffrey M. Herz
  • Patent number: 6645967
    Abstract: Described herein is a method for potentiating the action of a serotonin reuptake inhibitor in increasing the availability of serotonin, norepinephrin and dopamine in the brain, by administering to a patient an effective amount of a compound of the formula wherein Ar′ is a mono or bicyclic aryl or heteroaryl radical substituted with one to three substituents selected from the group consisting of hydrogen, (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)alkylthio, (C2-C6)alkenyl, (C2-C6)alkynyl, (C1-C6)alkylhalo, (C3-C8)cycloalkyl, (C3-C8)cycloalkenyl or halo; R1 is hydrogen, (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)alkylthio; R2 is phenyl, naphthyl or (C3-C12)cycloalkyl substituted with one or two substituents selected from the group consisting of hydrogen (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)alkylthio, (C2-C6)alkenyl, (C2-C6)alkynyl, (C1-C6)alkylhalo, (C3-C8)cycloalkyl, (C3-C8)cycloalkenyl or halo; R3 is selected from the group consisting of hydrogen (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)alkylthio, (C
    Type: Grant
    Filed: December 18, 2001
    Date of Patent: November 11, 2003
    Assignee: Eli Lilly and Company
    Inventors: Daniel Timothy Kohlman, Yao-Chang Xu
  • Patent number: 6642235
    Abstract: Methods for treating humans suffering from, migraine headaches by inhibiting reuptake of norepinephrine are disclosed. The methods comprise a compound having a pharmacological selectivity of serotonin (Ki)/norepinephrine (Ki) of at least about 5000. Examples of such compounds include reboxetine, and more preferably optically pure (S,S) enantiomer of reboxetine.
    Type: Grant
    Filed: January 4, 2002
    Date of Patent: November 4, 2003
    Assignee: Pharmacia & Upjohn Company
    Inventors: Erik H. F. Wong, Saeeduddin Ahmed, Robert C. Marshall, Robert McArthur, Duncan P. Taylor
  • Patent number: 6632842
    Abstract: The present invention relates to a dual bronchodilator inhalation solution, system, kit and method for relieving bronchospasm in patients suffering from chronic obstructive pulmonary disease (COPD). In one alternative embodiment, the solution of the present invention is a prepackaged, sterile, premixed, premeasured single unit dose of albuterol and ipratropium bromide for patients suffering from COPD. The present solution may be free of antimicrobial preservatives, such as benzalkonium chloride. In another alternative embodiment, the solution of the present invention comprises about 2.50 mg albuterol and about 0.50 mg ipratropium bromide.
    Type: Grant
    Filed: June 3, 2002
    Date of Patent: October 14, 2003
    Assignee: Dey, L.P.
    Inventors: Imtiaz Chaudry, Partha Banerjee
  • Patent number: 6627625
    Abstract: Administration of &bgr;-lactam compounds including &bgr;-lactam antibiotics and &bgr;-lactamase inhibitors provides significant neurotropic effects in warm-blooded vertebrates evidenced inter alia by anxiolytic and anti-aggressive behavior modification and enhanced cognition. Therapeutic methods for using such compounds and their pharmaceutical formulations are described.
    Type: Grant
    Filed: August 16, 2000
    Date of Patent: September 30, 2003
    Assignee: Revaax Pharmaceuticals, LLC
    Inventor: Gary A. Koppel
  • Patent number: 6610690
    Abstract: This application relates to methods for treating humans suffering from, fibromyalgia or other somatoform disorders where inhibiting reuptake of norepinephrine is a benefit. The methods comprise a compound having a pharmacological selectivity of serotonin (K1)/norepinephrine (K1) of at least about 5000. Examples of such compounds include reboxetine, and more preferably optically pure (S,S) enantiomer of reboxetine.
    Type: Grant
    Filed: January 4, 2002
    Date of Patent: August 26, 2003
    Assignee: Pharmacia & Upjohn Company
    Inventors: Erik H. F. Wong, Saeeduddin Ahmed, Robert C. Marshall, Robert McArthur, Duncan P. Taylor
  • Patent number: 6608103
    Abstract: This invention relates to an inhibitor having inhibitory activity against neovasculation, cell multiplication, lumen formation and fibroblast growth factor which comprises &bgr;-, &ggr;- or &dgr;-tocotrienol.
    Type: Grant
    Filed: February 1, 2002
    Date of Patent: August 19, 2003
    Assignees: Fuji Chemical Industry Co., Ltd.
    Inventors: Teruo Miyazawa, Heiji Ikushima
  • Patent number: 6608088
    Abstract: Methods of use of donepezil having central action for the treatment of function (migraine and primary fibromyalgia) and/or organic (amputation, “phantom limb”, tumoral or traumatic denervation or autoimmune mechanism) central pain syndromes are disclosed.
    Type: Grant
    Filed: May 7, 2001
    Date of Patent: August 19, 2003
    Assignee: Eisai., Ltd.
    Inventors: Maria Nicolodi, Federigo Sicuteri
  • Patent number: 6602888
    Abstract: A method of treating benign prostatic hyperplasia in a subject which comprises administering to the subject a therapeutically effective amount of a compound which binds to a human &agr;1C adrenergic receptor with a binding affinity greater than ten-fold higher than the binding affinity with which the compound binds to a human &agr;1A adrenergic receptor, a human &agr;1B adrenergic receptor, and a human histamine H1 receptor, and, binds to a human &agr;2 adrenergic receptor with a binding affinity which is greater than ten-fold lower than the binding affinity with which the compound binds to such &agr;1C adrenergic receptor. Compounds meeting these criteria are provided.
    Type: Grant
    Filed: November 22, 1999
    Date of Patent: August 5, 2003
    Assignee: Synaptic Pharmaceutical Corporation
    Inventors: Charles Gluchowski, Carlos C. Forray, George Chiu, Theresa A. Branchek, John M. Wetzel, Paul R. Hartig
  • Patent number: 6596754
    Abstract: The present invention relates to a preventive and/or therapeutic drug for hypercytokinemia, liver diseases, and syndromes caused by the aggravation of sepsis, containing an anti-thrombin agent and/or a thrombin production inhibitor as an active ingredient. The present invention is applicable to prevention of or therapy for diseases such as sepsis, severe sepsis, septic shock, and multiple organ dysfunction syndrome. More particularly, the present invention is useful for an emergency medical service, for treatment of injury caused by a traffic accident, burns, heat attacks, or severe infective diseases. In addition, the present invention is useful for prevention and treatment for hypercytokinemia and liver diseases.
    Type: Grant
    Filed: March 2, 2001
    Date of Patent: July 22, 2003
    Assignee: Daiichi Pharmaceuticals Co., Ltd.
    Inventors: Tsuyoshi Hara, Kazuko Fujiwara
  • Patent number: 6596306
    Abstract: This invention relates to a novel formulation for fat-soluble drugs which self-emulsify in the presence of an aqueous medium with little agitation. More specifically, the invention is concerned with the formulation of a new dosage form for fat-soluble drugs in the form of a soft-gelatin capsule which forms emulsion instantly when the contents are released and mixed with gastrointestinal fluid. The formulation comprises a suitable mixture of drug with an appropriate oil and an appropriate surfactant system.
    Type: Grant
    Filed: July 7, 2000
    Date of Patent: July 22, 2003
    Inventors: David Ho Sue San Ho, Yuen Kah Hay Yuen, Yap Siew Ping Yap
  • Patent number: 6593373
    Abstract: A method of producing pharmaceutical compositions using O-desmethyl-N-mono-desmethyl-tramadol for the treatment of pain and various related indications, pharmaceutical compositions containing O-desmethyl-N-mono-desmethyl-tramadol, and a method of treating pain, urinary incontinence, diarrhea or pruritus using O-desmethyl-N-mono-desmethyl-tramadol.
    Type: Grant
    Filed: October 12, 2001
    Date of Patent: July 15, 2003
    Assignee: Gruenenthal GmbH
    Inventors: Babette Koegel, Werner Englberger, Hagen-Heinrich Hennies, Elmar Friderichs
  • Patent number: 6589985
    Abstract: This invention is directed to a method for preventing or treating movement disorders comprising administering to a subject in need thereof a therapeutically effective amount of a compound selected from the group consisting of Formula (I) and Formula (II): wherein phenyl is substituted at X with one to five halogen atoms selected from the group consisting of fluorine, chlorine, bromine and iodine; and, R1, R2, R3, R4, R5 and R6 are independently selected from the group consisting of hydrogen and C1-C4 alkyl; wherein C1-C4 alkyl is optionally substituted with phenyl (wherein phenyl is optionally substituted with substituents independently selected from the group consisting of halogen, C1-C4 alkyl, C1-C4 alkoxy, amino, nitro and cyano).
    Type: Grant
    Filed: February 21, 2002
    Date of Patent: July 8, 2003
    Assignee: Ortho-McNeil Pharmaceutical, Inc.
    Inventors: Carlos R. Plata-Salaman, Boyu Zhao, Roy E. Twyman
  • Patent number: 6589982
    Abstract: Flavones with an isoprenyl group in the 8-position possess very good anti-inflammatory properties and can also be used to treat/prevent/cure skin-disorders when applied in food compositions.
    Type: Grant
    Filed: September 20, 2001
    Date of Patent: July 8, 2003
    Assignee: Lipton, division of Conopco, Inc.
    Inventors: Robert Mark Donovan, Martin Richard Green, Maria Catherine Tasker, Paula Rachel Yates
  • Patent number: 6589989
    Abstract: The invention is related to a method of treating chronic hand eczema in a human patient in need of treatment, using oral administration of 9-cis retinoic acid and pharmaceutically acceptable salts and pharmaceutically acceptable hydrolysable esters thereof, in an effective amount of from 0.05 to 1.5 milligrams per kilogram body weight per day.
    Type: Grant
    Filed: April 7, 2000
    Date of Patent: July 8, 2003
    Assignee: Basilea Pharmaceutica AG
    Inventors: Werner Bollag, Fritz Ott
  • Patent number: 6586440
    Abstract: This invention relates to pharmaceutical compositions of 5-alkynyluracil compounds in the form of tablets or capsules.
    Type: Grant
    Filed: April 23, 2001
    Date of Patent: July 1, 2003
    Assignee: SmithKline Beecham Corporation
    Inventors: Thomas Spector, David J. T. Porter, Saad George Rahim